К вопросу о патогенезе и лечении асимметричной гипертрофии левого желудочка при эссенциальной гипертензии
https://doi.org/10.18705/1607-419X-2008-14-4-360-368
Аннотация
Об авторах
А. В. БарсуковРоссия
Е. В. Пронина
Россия
С. Б. Шустов
Россия
Список литературы
1. Koren M., Devereux R. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114(5):345352.
2.
3. Levy D., Anderson K.M., Savage D.D. et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heat Study. Am J Cardiol 2000;285:92.
4.
5. Cruickshank J.M., Lewis J., Moore V. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;65:85-90.
6.
7. Dahlof B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am Heart Hypertens 1992;5:95-110.
8.
9. Verdecchia P. Controlling blood pressure in patients with left ventricular hypertrophy. Renin angiotensin system in cardiovascular medicine. 2006;2(3):2-5.
10.
11. Hill D.J., Millner D.J. Insulin as a growth factor. Pediatr Res 1985;19:879-886.
12.
13. Fagard R., Staessen J., Thijs S. et al. Multiple standardized clinic blood pressures may predict left ventricular mass as well as ambulatory monitoring. Am J Hypertens 1995;8:533−540.
14.
15. Schmeider R.E., Schlaich M.P., Klingbeil A.U. et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998;13:564−569.
16.
17. Grassi G. Renin-angiotensin-sympathetic cross-talks in hypertension: reappraising the relevance of peripheral interactions. J Hypertens 2001;19:1713−1716.
18.
19. Conen D., Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens 2008;26:1290−1299.
20.
21. Palatini P. Ambulatory blood pressure monitoring in clinical practice: being superior good enough. J Hypertens 2008;26:1300−1302.
22.
23. Ruilop L.M. Aldosterone, hypertension, and cardiovascular disease. Hypertension 2008;52:207−208.
24.
25. Шляхто Е.В., Конради А.О. Ремоделирование сердца при гипертонической болезни. Сердце 2002;1(5):232−234.
26.
27. Barsukov A., Pronina E., Shoustov S., Kursina L., Eliseeva T. Asymmetric left ventricle hypertrophy in essential hypertension: electrocardiographic data. J Hypertens 2006;24(suppl. 4):121.
28.
29. Шиллер Н., Осипов М.А. Клиническая эхокардиография. М: Практика;2005:344 с.
30.
31. Reichek N., Devereux R.B. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 1981;63:1391−1398.
32.
33. Ganau A., Devereux R.B., Pickering T.G et al. Relation of left ventricular hemodynamic load and contractile performance of left ventricular mass in hypertension. Circulation 1990;81:25−36.
34.
35. Кувакин В. И. Математико-статистические методы в клинической практике. СПб: Воен.-мед. акад;1993:200 с.
36.
37. Сергиенко В.И., Бондарева И.Б. Математическая статистика в клинических исследованиях. М: ГЕОТАР-МЕД;2001:256 с.
38.
39. Шулутко Б.И. Внутренняя медицина. СПб: Левша;1999;Т.1:511 с.
40.
41. Козина А.А. Взаимосвязь структурно-геометрических показателей, систолической и диастолической функций левого желудочка при ишемической болезни сердца и артериальной гипертензии: Автореф. дис. канд. мед. наук. М;2003:29 с.
42.
43. Verdecchia P., Schillaci G., Reboldi G et al. Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance of hypertension. A case-control study. Blood Press Monit 2000;5:187−193.
44.
45. Muller-Brunotte R., Kahan T., Lopez B. et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan left ventricular hypertrophy investigation versus Atenolol (SILVHIA). J Hypertens 2007;25:1958−1966.
46.
47. Vuscholl M.W. et al. Changes in left ventricular structure and function in patients with white coat hypertension: cross sectional survey. BMJ 1998;317(7158):565-570.
48.
49. Biederman R.W.W., Doyle M., Young A.A. et al. Marked Regional Left Ventricular Heterogeneity in Hypertensive Left Ventricular hypertrophy Patients. Hypertension 2008;52:279−286.
50.
51. Masuama T., St Goar F.G., Tye T.L. et al. Ultrasonic tissue characterization of human hypertrophied hearts in vivo with cardiac cycle-dependent variation in integrated backscatter. Circulation 1989;80:925−934.
52.
53. Devereux R.B, Roman M.J. Hypertensive cardiac hypertrophy: pathophysiologic and clinical characteristics. In Laragh J.H., Brenner B.M., editors. Hypertension: pathophysiology, diagnosis and management treatment. 2nd ed. New York: Raven Press; 1995:409−422.
54.
55. Алмазов В.А., Цырлин В.А. Нейрогуморальные механизмы реконструкции сосудов и сердца при артериальной гипертензии. Артериальные гипертензии (актуальные вопросы патогенеза): Сб. Науч. Tр. СПб;1995:7−22.
56.
57. Mancia G, Bousquet P, Elghozi et al. The sympathetic nervous system and metabolic syndrome. J Hypertens 2007;25:909−920.
58.
59. Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural, and endocrine dependence. Circulation 1991;83:13−25.
60.
61. Vasan RS, Evans JC, Larson MG et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. New Engl J Med 2006;351:33−41.
62.
63. Geisterfer A.A.T., Peach M.J., Owens G.K. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988;62:749−756.
64.
65. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994;93:2578−2583.
66.
67. Navarro-Lopez F, Coca A, Pare JC et al. Left ventricular hypertrophy in asymptomatic essential hypertension: its relationship with aldosterone and the increase in sodium-proton exchanger activity. Eur Heart J 1993;14(Suppl J):38−41.
68.
69. Барсуков А.В. Состояние сердечно-сосудистой и нейрогуморальной регуляторной систем у лиц молодого возраста с различной степенью стабильности гипертензионного синдрома: Автореф. дис. докт. мед. наук. 2001:48 с.
70.
71. Lind L., Andersson P.E., Andren B. et al. Left ventricular hypertrophy in hypertension is associated with insulin resistance metabolic syndrome. J Hypertens 1995;13:433−438.
72.
73. Verdecchia P., Reboldi G., Schillaci G. et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999;100:1802−1807.
74.
75. Lopez B., Querejeta R., Varo N. et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001;104:286−291.
76.
77. Perlini S., Muiesan M.L., Cuspidi C. et al. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation 2001;103:678−683.
78.
79. Schmieder R., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: meta-analysis of randomized studies. JAMA 1996;275(19):1507−1503.
80.
81. Klingbeil A.U., Schneider M., Martus P. et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115(1):41−46.
82.
83. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388−1393.
84.
85. Jonston C.I. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens Suppl 1989;7(5):S11−16.
86.
87. Franz I.W., Tonnesmann U., Muler J.F. Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors. Am J Hypertens 1998;11(6 Pt 1):631−9.
88.
89. Lemarie C.A., Paradis S., Schiffrin E.L. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med 2008;86:673−678.
90.
91. Graf K., Hucko T., Stawowy P. Cardiac Benefits of mineralocorticoid receptor inhibition in renal failure. Hypertension 2008;52:209−210.
92.
93. Cox B.F., Bishop V.S. Neural and humoral mechanisms of angiotensin-dependent hypertension. Am J Physiol1991;261(4) (Pt 2):H1284−Н1291.
94.
95. Brunner H.R., Gavras H., Mimran A. Eprosartan Monograph. London, 2000:250 p.
96.
97. Grassi G. Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens 2004;13:513−519.
98.
99. DeFronzo R.A, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173−194.
100.
101. Sowers J.R. et al. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004;286:H1597−1602.
102.
103. Folli F., Kahn C.R, Hansen H. et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997;100(9):2158−2169.
104.
Рецензия
Для цитирования:
Барсуков А.В., Пронина Е.В., Шустов С.Б. К вопросу о патогенезе и лечении асимметричной гипертрофии левого желудочка при эссенциальной гипертензии. Артериальная гипертензия. 2008;14(4):360-368. https://doi.org/10.18705/1607-419X-2008-14-4-360-368
For citation:
Barsukov A., Pronina E..., Shoustov S... Actual aspects of pathogenesis and treatment of asymmetric left ventricular hypertrophy in essential hypertension. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2008;14(4):360-368. (In Russ.) https://doi.org/10.18705/1607-419X-2008-14-4-360-368